Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198469 | 0.84 | FASN (0.40) | KDM1AFPR2FGFR2FGFR1FFAR4 | |
| SCHEMBL9927669 | 0.83 | FASN (0.42) | KDM1AFPR2FGFR2FGFR1FFAR4 | |
| SCHEMBL13579371 | 0.82 | FPR2 (0.34) | KDM1AFPR2 | |
| SCHEMBL13579521 | 0.82 | FPR2 (0.34) | KDM1AFPR2 | |
| SCHEMBL20111482 | 0.82 | PRKAG1 (0.39) | KDM1AFGFR2PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL19466413 | 0.82 | KDM1A (0.35) | KDM1AFPR2FGFR2FGFR1FFAR4 | |
| SCHEMBL13579372 | 0.81 | FPR2 (0.33) | KDM1AFPR2 | |
| SCHEMBL13579523 | 0.81 | FPR2 (0.33) | KDM1AFPR2 | |
| SCHEMBL12032722 | 0.81 | SLC6A2 (0.38) | KDM1AFPR2FGFR2FGFR1FFAR4 | |
| SCHEMBL9898150 | 0.81 | FASN (0.35) | KDM1AFPR2FFAR4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468740-B1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9663716-B2 | Tetrahydropyran compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| EP-2468740-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | JNC Corporation (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120145958-A1 | TETRAHYDROPYRAN COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, CCND1, CCND2 | KDM1A 2319/4885FPR2 442/4885FGFR2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.